Evidence map›Paper›PMID 31736654›Full record

ArticleMediators of inflammation2019

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis.

I Wojsyk-Banaszak, P Sobkowiak, K Jończyk-Potoczna, B Narożna, W Langwiński, M Szczepanik, Z Kycler, A Bręborowicz, A Szczepankiewicz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. The Emerging Role of Copeptin.The Clinical biochemist. Reviews · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

I Wojsyk-BanaszakDepartment of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.
P SobkowiakDepartment of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0003-2737-8946
K Jończyk-PotocznaDepartment of Pediatric Radiology, Poznan University of Medical Sciences, Poznań, Poland.
B NarożnaLaboratory of Molecular and Cell Biology, Department of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0002-1172-6312
W LangwińskiLaboratory of Molecular and Cell Biology, Department of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0003-4906-7225
M SzczepanikDepartment of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poznań, Poland.
Z KyclerDepartment of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0002-4870-7043
A BręborowiczDepartment of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0001-7811-7565
A SzczepankiewiczLaboratory of Molecular and Cell Biology, Department of Pulmonology, Pediatric Allergy and Clinical Immunology, Poznan University of Medical Sciences, Poznań, Poland.ORCID https://orcid.org/0000-0003-3379-9106
Poznan University of Medical Sciences · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Copeptin was found to be a stable biomarker of inflammation and stress response in cardiac, renal, metabolic, and respiratory conditions such as pneumonia. The aim of this study was to investigate the copeptin levels in biological fluids (serum and sputum supernatant) of cystic fibrosis pediatric patients during pulmonary exacerbation and remission and to investigate the possible influence of copeptin levels on disease severity and quality of life. Copeptin serum concentrations were measured in 28 pediatric cystic fibrosis (CF) patients: 13 in stable condition and 15 during pulmonary exacerbation. In 10 CF patients, copeptin was also measured in the sputum. In all the patients, we assessed complete blood count, BMI, sputum culture, lung function, and chest imaging (with Brasfield score). The severity of symptoms was assessed using the Shwachman-Kulczycki (SK) score, and the quality of life was assessed with the Cystic Fibrosis Quality of Life Questionnaire-Revised (CFQ-R). Copeptin concentrations in serum and sputum supernatant was measured using an ELISA kit. Statistical analysis was done in Statistica v.12. Serum and sputum copeptin levels were higher in CF patients during pulmonary exacerbation than in a stable period, but the differences were not significant (

Indexed as

Analysis of VarianceCystic FibrosisFemaleForced Expiratory VolumeGlycopeptidesHumansMaleProspective StudiesRespiratory Function TestsSurveys and QuestionnairescopeptinsGlycopeptides

Identifiers

PMID31736654
PMCPMC6816008
OpenAlexW2981230849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.